Heartflow's quarterly loss widened over the year-ago period, the healthcare company disclosed in its paperwork for a U.S.

Heartflow is once again looking for a path to go public, with a filing for a Nasdaq IPO. | The former Fierce Medtech Fierce ...

This summary covers significant health news including FDA advisers rejecting Otsuka's PTSD treatment, Getinge exceeding ...

In a bold bid to electrify Wall Street and revolutionize how heart disease is diagnosed, Heartflow, a medical technology ...

Heartflow has filed for an initial public offering. The company recorded sales of $125.8 million and a net loss of $96.4 million last year, according to a filing with the Securities and Exchange ...

The U.S. IPO market is witnessing a renewed vigor as investors return following months of sluggish activity triggered by ...

Heartflow Holding Inc. is aiming to bring its noninvasive, artificial intelligence (AI)-based test for coronary heart disease to more doctors and patients via a merger with Longview Acquisition Corp.

Such well-funded companies are ripe targets for IPO. Heartflow has been venture-backed since 2009, ramped up the amounts it has raised consistently – with a $100+ million round that wrapped up ...

The firm found that companies tended to IPO at an age of about 10 years and after raising roughly $200 million. ... HeartFlow has a $1.56 billion valuation, according to PitchBook.

Heartflow Holding Inc. is aiming to bring its noninvasive, artificial intelligence (AI)-based test for coronary heart disease to more doctors and patients via a merger with Longview Acquisition Corp.